DMK

Gainers Sharps Technology (NASDAQ:STSS) stock increased by 27.9% to $0.37 during Tuesday's after-market session. The company's market cap stands at $5.6 million. DMK Pharmaceuticals (NASDAQ:DMK) stock moved upwards by 22.84% to $0.28. The company's market cap stands at $2.8 million. Mira Pharmaceuticals (NASDAQ:MIRA) stock rose 11.6% to $1.25. The company's market cap stands at $18.4 million. Vicarious Surgical (NYSE:RBOT) shares increased by 5.4% to $0.43. The company's market cap stands at $74.7 million. Novo Integrated Sciences (NASDAQ:NVOS) stock increased by 4.97% to $0.77. The company's market cap stands at $13.7 million. Galecto (NASDAQ:GLTO) stock moved upwards by 4.82% to $0.6

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 200 points on Monday. The Dow traded down 0.53% to 38,450.28 while the NASDAQ fell 0.11% to 15,612.52. The S&P 500 also fell, dropping, 0.16% to 4,950.80. Check This Out: Pinterest To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Monday   Leading and Lagging Sectors   Information technology shares rose by 0.6% on Monday. In trading on Monday, materials shares fell by 2.4%.   Top Headline   Caterpillar Inc (NYSE:CAT) posted better-than-expected earnings for its fourth quarter on Monday. Caterpillar reported a fourth-quarter fiscal 2023 revenue increase of 3% year-over-year to $17.

Shares of Air Products and Chemicals, Inc. (NYSE:APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS guidance below estimates. Air Products & Chemicals posted adjusted earnings of $2.82 per share, missing market estimates of $3.00 per share. The company’s quarterly sales came in at $3.00 billion versus expectations of $3.19 billion. Air Products and Chemicals shares dipped 14.7% to $220.02 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Yield10 Bioscience, Inc. (NASDAQ:YTEN) shares climbed 116.4% to $0.4964. 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT

Gainers 4D Molecular Therapeutics (NASDAQ:FDMT) stock increased by 75.2% to $30.64 during Monday's regular session. The company's market cap stands at $1.3 billion. Yield10 Bioscience (NASDAQ:YTEN) stock rose 61.76% to $0.37. The market value of their outstanding shares is at $4.4 million. MorphoSys (NASDAQ:MOR) stock moved upwards by 50.76% to $16.69. The market value of their outstanding shares is at $2.5 billion. Karyopharm Therapeutics (NASDAQ:KPTI) shares moved upwards by 31.73% to $1.37. The company's market cap stands at $156.9 million. Adverum Biotechnologies (NASDAQ:ADVM) stock moved upwards by 28.86% to $1.83. The company's market cap stands at $184.8 million. Mira Pharmaceut

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday. The Dow traded down 1.04% to 38,253.72 while the NASDAQ fell 0.86% to 15,493.97. The S&P 500 also fell, dropping, 0.70% to 4,923.81. Check This Out: Pinterest To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Monday   Leading and Lagging Sectors   Health care shares rose by 0.4% on Monday. In trading on Monday, materials shares fell by 2.6%.   Top Headline   The ISM services PMI for the US rose to 53.4 in January versus 50.5 in the prior month, and topping market estimates of 52.   Equities Trading UP   Everbridge, Inc. (NASDAQ:EVBG) shares shot up 18% t

U.S. stocks traded lower this morning, with the Dow Jones index falling around 150 points on Monday. Following the market opening Monday, the Dow traded down 0.41% to 38,494.03 while the NASDAQ fell 0.15% to 15,605.04. The S&P 500 also fell, dropping, 0.18% to 4,949.49. Check This Out: Pinterest To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Monday   Leading and Lagging Sectors   Health care shares rose by 0.6% on Monday. In trading on Monday, materials shares fell by 2.4%.   Top Headline   McDonald’s Corporation (NYSE:MCD) posted weaker-than-expected sales for its fourth quarter. McDonald’s reported adjusted EPS of $2.95, beating the consensus of $2.82. Sales of $6.

Gainers 4D Molecular Therapeutics (NASDAQ:FDMT) stock rose 60.1% to $28.0 during Monday's pre-market session. The market value of their outstanding shares is at $1.1 billion. Yield10 Bioscience (NASDAQ:YTEN) shares increased by 48.47% to $0.34. The market value of their outstanding shares is at $4.0 million. BioRestorative Therapies (NASDAQ:BRTX) shares increased by 34.64% to $3.77. The market value of their outstanding shares is at $17.7 million. Adverum Biotechnologies (NASDAQ:ADVM) stock increased by 16.19% to $1.65. The company's market cap stands at $166.6 million. Rani Therapeutics Hldgs (NASDAQ:RANI) shares moved upwards by 13.18% to $3.95. The market value of their outstanding s

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) rose sharply in today’s pre-market trading. 4DMT presented interim data from randomized Phase 2 PRISM clinical trial of intravitreal 4D-150 demonstrating favorable tolerability & clinical activity in wet AMD. 4D Molecular Therapeutics shares jumped 20.1% to $21.01 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Chenghe Acquisition Co. (NASDAQ:CHEA) gained 68.1% to $9.23 in pre-market trading after dipping around 46% on Friday. Tritium DCFC Limited (NASDAQ:DCFC) shares jumped 51.9% to $0.1990 in pre-market trading. Tritium DCFC said the company was the top-awarded fast charger manufacturer f

Gainers Karuna Therapeutics (NASDAQ:KRTX) stock moved upwards by 47.9% to $318.17 during Friday's pre-market session. The company's market cap stands at $12.0 billion. Senti Biosciences (NASDAQ:SNTI) stock moved upwards by 29.29% to $0.57. The market value of their outstanding shares is at $25.2 million. SenesTech (NASDAQ:SNES) stock increased by 23.89% to $0.94. Galecto (NASDAQ:GLTO) shares increased by 19.81% to $0.74. The market value of their outstanding shares is at $20.1 million. TC BioPharm (Holdings) (NASDAQ:TCBP) stock increased by 15.99% to $2.9. The company's market cap stands at $1.9 million. Reviva Pharmaceuticals (NASDAQ:RVPH) shares moved upwards by 14.28% to $4.4. The c

Gainers NuCana (NASDAQ:NCNA) shares rose 15.6% to $0.35 during Thursday's after-market session. The market value of their outstanding shares is at $18.2 million. Galecto (NASDAQ:GLTO) stock increased by 14.28% to $0.72. The company's market cap stands at $19.5 million. Ensysce Biosciences (NASDAQ:ENSC) shares rose 9.51% to $1.15. The company's market cap stands at $3.6 million. Atara Biotherapeutics (NASDAQ:ATRA) stock increased by 9.39% to $0.49. The company's market cap stands at $49.7 million. 60 Degrees (NASDAQ:SXTP) stock moved upwards by 8.18% to $1.19. The market value of their outstanding shares is at $6.9 million. PetVivo Hldgs (NASDAQ:PETV) stock moved upwards by 7.75% to $1.

Shares of CarMax, Inc. (NYSE:KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings. KMX reported a third-quarter sales decline of 5.5% year-on-year to $6.15 billion, missing the analyst consensus estimate of $6.33 billion. EPS of $0.52 beat the consensus estimate of $0.44. CarMax shares climbed 7.7% to $80.42 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Infrared Cameras Holdings Inc (NASDAQ:MSAI) shares jumped 222% to $8.43 after falling over 61% on Wednesday. HOOKIPA Pharma Inc. (NASDAQ:HOOK) surged 75% to $0.9874 after the company announced a $21.25 million equity investment from Gilead Sciences. DMK Ph

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Thursday. The Dow traded up 0.58% to 37,296.40 while the NASDAQ rose 0.77% to 14,891.87. The S&P 500 also rose, gaining, 0.68% to 4,730.26. Check This Out: Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday   Leading and Lagging Sectors   Health care shares jumped by 1% on Thursday. In trading on Thursday, energy shares fell by 0.1%.   Top Headline   Micron Technology, Inc. (NASDAQ:MU) reported mixed first-quarter financial results and issued strong guidance on Wednesday. Micron reported first-quarter revenue of $4.73 billion, which beat the conse

DMK Pharmaceuticals Corporation (NASDAQ:DMK) shares are trading higher Thursday after the company announced that it has regained the full rights to commercialize Zimhi (naloxone) after the termination of an exclusive commercialization and distribution agreement with US WorldMeds, LLC. What To Know: DMK Pharmaceuticals announced the termination of the exclusive agreement and the company is actively seeking commercialization opportunities for Zimhi, in the U.S., Canada and Europe. DMK Pharmaceuticals shares are blasting higher on heavy trading volume following the announcement. According to data from Benzinga Pro, more than 27.4 million shares have been traded in the session, far exceeding

U.S. stocks traded higher this morning, with the Dow Jones gaining around 250 points on Thursday. Following the market opening Thursday, the Dow traded up 0.72% to 37,348.90 while the NASDAQ rose 0.96% to 14,919.80. The S&P 500 also rose, gaining, 0.78% to 4,734.96. Check This Out: Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday   Leading and Lagging Sectors   Information technology shares jumped by 1.1% on Thursday. In trading on Thursday, energy shares rose by just 0.3%.   Top Headline   U.S. initial jobless claims rose by 2,000 to 205,000 in the week ending Dec. 16, compared to market expectations of 215,000.   Equities Trading UP   Infrared Ca

DMK Pharmaceuticals Corporation (NASDAQ:DMK) ("DMK"), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, announces that it has regained the full rights to commercialize ZIMHI® (naloxone) after the termination of an exclusive commercialization and distribution with US WorldMeds, LLC. DMK is now actively seeking commercialization opportunities for ZIMHI, in the United States, Canada, and Europe, focused on new, near-term revenues. In the United States, first responders are the primary target for ZIMHI, where market data demonstrates significant, unmet demand.Eboo Versi, M.D., Ph

SAN DIEGO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ:DMK) ("DMK"), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, announces that it has regained the full rights to commercialize ZIMHI® (naloxone) after the termination of an exclusive commercialization and distribution with US WorldMeds, LLC. DMK is now actively seeking commercialization opportunities for ZIMHI, in the United States, Canada, and Europe, focused on new, near-term revenues. In the United States, first responders are the primary target for ZIMHI, where market data demonstrate

Maxim Group analyst Michael Okunewitch initiates coverage on DMK Pharmaceuticals (NASDAQ:DMK) with a Buy rating and announces Price Target of $1.5.

The Company is now actively seeking out-license opportunities for SYMJEPI® in the US and globally, in addition to exploring other options with a focus on maximizing value for shareholders.

SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ:DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, today announced that it is reacquiring the rights to its SYMJEPI® (epinephrine) Injection 0.3mg and SYMJEPI® (epinephrine) Injection 0.15mg products from USWM, LLC ("USWM" or "US WorldMeds"). US WorldMeds previously held exclusive distribution and commercialization rights for SYMJEPI® and ZIMHI® (naloxone) products in the United States, and was responsible for marketing, promotion and distribution efforts. The Company is now act

DMK Pharmaceuticals (NASDAQ:DMK) reported quarterly losses of $(0.20) per share. This is a 90.24 percent increase over losses of $(2.05) per share from the same period last year. The company reported $9.06 thousand in sales this quarter. This is a 99.40 percent decrease over sales of $1.51 million the same period last year.

Rebranded company to DMK Pharmaceuticals and appointed inaugural, passionate and committed leadership team to execute on new strategy to reduce opioid related deaths through enhanced sales of ZIMHI® and thus increase shareholder value Developed holistic company growth strategy to create a cost effective, coordinated, streamlined approach to operations to increase value for patients and shareholders Presented preclinical data for DPI-125 at the Society of Neuroscience Annual Meeting 2023 on November 13, 2023; results supported further development of DPI-125 as a potential treatment of opioid use disorder SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) --  DMK Pharmaceuticals Corporation (NASD

DMK Pharmaceuticals Corporation (NASDAQ:DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, today announced the presentation of preclinical results comparing the effects of DPI-125 on opioid withdrawal behaviors to methadone and buprenorphine, the standard of care for opioid use disorder (OUD), in a poster session at the Society for Neuroscience Annual Meeting (SfN Neuroscience 2023) held November 11-13, 2023 in Washington D.C. DPI-125 is a novel, small-molecule triple (mu, delta and kappa) opioid receptor agonist, being developed for the treatment of opioid use disorder.

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ:DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, today announced the presentation of preclinical results comparing the effects of DPI-125 on opioid withdrawal behaviors to methadone and buprenorphine, the standard of care for opioid use disorder (OUD), in a poster session at the Society for Neuroscience Annual Meeting (SfN Neuroscience 2023) held November 11-13, 2023 in Washington D.C. DPI-125 is a novel, small-molecule triple (mu, delta and kappa) opioid receptor agonist, being deve

SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ:DMK), a commercial-stage biopharmaceutical company, today announced that the compensation committee of the board of directors approved the grant of a stock option on October 23, 2023, to purchase an aggregate of 70,000 shares of common stock to John W. Dorbin, Jr., a newly hired employee who was appointed as General Counsel and Corporate Secretary of the company. The stock option was granted as a material inducement to his acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has a ten-year term and has an exercise price of $0.58 per share, the closing price of the co